Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 75.49 as of 2026-10-06T15:47:17.417Z.
Consensus retrieved: 2026-10-06T13:26:08.695Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:47:17.417Z.
Quote observation: 2026-10-06T15:45:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 86267c31300e5632118d853975c1c782a695d65279c84a9c7564e72742fbe414
Forward PE Ratio (75.49) = Dated Quote Price ($12.12) / Consensus Forward EPS ($0.16)
FORWARD PE RATIO
75.49
SECTOR MEDIAN · HEALTHCARE
19.77
median of 171 covered companies
CURRENT VS SECTOR MEDIAN
+281.84%
vs the sector median at left
LifeStance Health Group, Inc.
Market Cap
$4.70B
Forward PE Ratio
75.49
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| LifeStance Health Group, Inc. (LFST) | $4.70B | 75.49 |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.75B | N/A |
| Option Care Health, Inc. (OPCH)vs › | $4.65B | 16.50 |
| BillionToOne, Inc. (BLLN)vs › | $4.62B | 126.39 |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.86B | N/A |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.88B | N/A |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.92B | N/A |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.45B | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.44B | 8.43 |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.38B | N/A |
Trailing P/E
93.4
reported TTM EPS
Forward P/E
75.5
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.16 implies +23.1% EPS growth vs the reported trailing $0.13.
At the dated quote price of $12.12, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.16 | $0.14 – $0.17 | 5 | 75.5x |
| 2027-12-31 | $0.22 | $0.21 – $0.23 | 5 | 55.2x |
| 2028-12-31 | $0.44 | $0.34 – $0.54 | 5 | 27.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
